ngm438
mAbexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 11, 2022 (NCT05311618)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Cholangiocarcinoma · Phase 1
- Colorectal Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Melanoma · Phase 1
- Mesothelioma · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Stomach Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05311618 | Phase 1 | May 11, 2022 | Merck, NGM Biopharmaceuticals, Inc |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 1 | 0 | 1 | 2022 |
| NGM Biopharmaceuticals, Inc | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1